CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy

• Published in: Annals of surgical oncology Vol. 23; no. Suppl 5; pp. 746 - 754
• Main Authors: Fisher, Oliver M., Levert-Mignon, Angelique J., Lehane, Christopher W., Botelho, Natalia K., Maag, Jesper L. V., Thomas, Melissa L., Edwards, Melanie, Lord, Sarah J., Bobryshev, Yuri V., Whiteman, David C., Lord, Reginald V.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-12-2016; Springer Nature B.V
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Aged; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms - genetics; Esophageal Neoplasms - metabolism; Esophageal Neoplasms - pathology; Esophageal Neoplasms - therapy; Esophagectomy; Esophagogastric Junction; Female; Gastrointestinal Oncology; Gene Expression; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Oncology; Prognosis; Proportional Hazards Models; Surgery; Surgical Oncology; Survival Rate; Tetraspanin 24 - genetics; Tetraspanin 24 - metabolism; Multimodality Therapy; CD151 Protein Expression; Gene Expression Omnibus; Validation Cohort; Resection Margin Status
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-016-5504-9

Background
Esophageal and gastroesophageal junctional (GEJ) adenocarcinoma is one of the most fatal cancers and has the fastest rising incidence rate of all cancers. Identification of biomarkers is needed to tailor treatments to each patient’s tumor biology and prognosis.
Methods
Gene expression profiling was performed in a test cohort of 80 chemoradiotherapy (CRTx)-naïve patients with external validation in a separate cohort of 62 CRTx-naïve patients and 169 patients with advanced-stage disease treated with CRTx.
Results
As a novel prognostic biomarker after external validation, CD151 showed promise. Patients exhibiting high levels of CD151 (≥median) had a longer median overall survival than patients with low CD151 tumor levels (median not reached vs. 30.9 months;
p
 = 0.01). This effect persisted in a multivariable Cox-regression model with adjustment for tumor stage [adjusted hazard ratio (aHR), 0.33; 95 % confidence interval (CI), 0.14–0.78;
p
 = 0.01] and was further corroborated through immunohistochemical analysis (aHR, 0.22; 95 % CI, 0.08–0.59;
p
 = 0.003). This effect was not found in the separate cohort of CRTx-exposed patients.
Conclusion
Tumoral expression levels of CD151 may provide independent prognostic information not gained by conventional staging of patients with esophageal and GEJ adenocarcinoma treated by esophagectomy alone.